HRP20211813T1 - Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 - Google Patents
Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 Download PDFInfo
- Publication number
- HRP20211813T1 HRP20211813T1 HRP20211813TT HRP20211813T HRP20211813T1 HR P20211813 T1 HRP20211813 T1 HR P20211813T1 HR P20211813T T HRP20211813T T HR P20211813TT HR P20211813 T HRP20211813 T HR P20211813T HR P20211813 T1 HRP20211813 T1 HR P20211813T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhibitor
- bcl
- btk
- use according
- compound
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title claims 12
- 229940123711 Bcl2 inhibitor Drugs 0.000 title claims 11
- 229940124291 BTK inhibitor Drugs 0.000 title claims 10
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 229940045793 B-cell lymphoma-2 inhibitor Drugs 0.000 claims 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 229960003347 obinutuzumab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229950000815 veltuzumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (10)
1. Farmaceutska kombinacija koja sadrži (1) inhibitor limfoma B-stanica 2 (BCL-2) ili njegovu farmaceutski prihvatljivu sol, i (2) inhibitor Brutonove tirozin kinaze (BTK) ili njegovu farmaceutski prihvatljivu sol, za uporabu u liječenju raka kod ljudskog subjekta, naznačena time što je inhibitor BCL-2 spoj s formulom:
[image]
i inhibitor BTK je spoj s formulom:
[image]
2. Farmaceutska kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što se inhibitor BCL-2 treba primijeniti prije primjene inhibitora BTK.
3. Farmaceutska kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što se inhibitor BCL-2 treba primijeniti istodobno s primjenom inhibitora BTK.
4. Farmaceutska kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što se inhibitor BCL-2 treba dati subjektu nakon primjene inhibitora BTK.
5. Farmaceutska kombinacija za uporabu u skladu s bilo kojim prethodnim patentnim zahtjevom, naznačena time što kombinacija nadalje sadrži anti-CD20 protutijelo odabrano iz skupine koju čine rituksimab, obinutuzumab, ofatumumab, veltuzumab, tositumomab i ibritumomab.
6. Farmaceutska kombinacija za uporabu u skladu s bilo kojim prethodnim patentnim zahtjevom, naznačena time što je rak hematološki malignitet odabran iz skupine koju čine kronična limfocitna leukemija (CLL), mala limfocitna leukemija (SLL), ne-Hodgkinov limfom (NHL), difuzni B velikostanični limfom (DLBCL), folikularni limfom (FL), limfom plaštene zone (MCL), Hodgkinov limfom, B stanična akutna limfoblastna leukemija (B-ALL), Burkittov limfom, Waldenströmova makroglobulinemija (WM), multipli mijelom, i mijelofibroza.
7. Farmaceutski pripravak koji sadrži (1) inhibitor BCL-2 ili njegovu farmaceutski prihvatljivu sol; i (2) inhibitor BTK ili njegovu farmaceutski prihvatljivu sol za uporabu u liječenju raka kod ljudskog subjekta, naznačen time što je inhibitor BCL-2 spoj s formulom:
[image]
i inhibitor BTK je spoj s formulom:
[image]
8. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 7, naznačen time što sadrži količinu inhibitora BTK odabranu iz skupine koja se sastoji od 5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, i 550 mg.
9. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 7, naznačen time što sadrži količinu inhibitora BCL-2 odabranu iz skupine koja se sastoji od 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, i 500 mg.
10. Komplet koji sadrži (1) pripravak koji sadrži inhibitor BCL-2 ili njegovu farmaceutski prihvatljivu sol; i (2 pri čemu je komplet za istodobnu primjenu inhibitora BCL-2 i inhibitora BTK, bilo istodobno ili odvojeno za uporabu u liječenju raka kod ljudskog subjekta, pri čemu je inhibitor BCL-2 spoj s formulom:
[image]
i inhibitor BTK je spoj s formulom:
[image]
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462035795P | 2014-08-11 | 2014-08-11 | |
US201462088240P | 2014-12-05 | 2014-12-05 | |
US201562115497P | 2015-02-12 | 2015-02-12 | |
US201562181160P | 2015-06-17 | 2015-06-17 | |
EP15757002.9A EP3179991B1 (en) | 2014-08-11 | 2015-08-11 | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
PCT/IB2015/056126 WO2016024230A1 (en) | 2014-08-11 | 2015-08-11 | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211813T1 true HRP20211813T1 (hr) | 2022-03-04 |
Family
ID=54015145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211813TT HRP20211813T1 (hr) | 2014-08-11 | 2015-08-11 | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20170231986A1 (hr) |
EP (1) | EP3179991B1 (hr) |
DK (1) | DK3179991T3 (hr) |
ES (1) | ES2900184T3 (hr) |
HR (1) | HRP20211813T1 (hr) |
HU (1) | HUE056329T2 (hr) |
LT (1) | LT3179991T (hr) |
PL (1) | PL3179991T3 (hr) |
PT (1) | PT3179991T (hr) |
RS (1) | RS62713B1 (hr) |
SI (1) | SI3179991T1 (hr) |
TW (1) | TW201618772A (hr) |
WO (1) | WO2016024230A1 (hr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG185617A1 (en) | 2010-05-31 | 2012-12-28 | Ono Pharmaceutical Co | Purinone derivative |
KR102021651B1 (ko) | 2011-11-29 | 2019-09-16 | 오노 야꾸힝 고교 가부시키가이샤 | 퓨리논 유도체 염산염 |
EP3122360B1 (en) | 2014-03-25 | 2020-06-17 | ONO Pharmaceutical Co., Ltd. | Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma |
EP3179991B1 (en) * | 2014-08-11 | 2021-10-06 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
JP6750613B2 (ja) | 2015-04-09 | 2020-09-02 | 小野薬品工業株式会社 | プリノン誘導体の製造方法 |
US20180353512A1 (en) * | 2015-06-23 | 2018-12-13 | Gilead Sciences, Inc. | Combination therapies for treating b-cell malignancies |
KR102545392B1 (ko) | 2016-03-28 | 2023-06-20 | 프레시지 바이오싸이언시스, 인크. | 암 치료를 위한 제약학적 조합물 |
US20190225607A1 (en) * | 2016-07-06 | 2019-07-25 | Concert Pharmaceuticals, Inc. | Deuterated Venetoclax |
EP3515911A1 (en) * | 2016-09-23 | 2019-07-31 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
JP7064495B2 (ja) | 2016-12-07 | 2022-05-10 | ベイジーン リミテッド | PI3Kδ阻害剤としてのイミダゾ[1,5-a]ピラジン誘導体 |
US11351176B2 (en) | 2017-08-14 | 2022-06-07 | Mei Pharma, Inc. | Combination therapy |
HUE061898T2 (hu) | 2017-09-08 | 2023-08-28 | Beigene Ltd | Imidazo[1,5-a]pirazin-származékok mint PI3Kdelta inhibitorok |
US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
KR102436875B1 (ko) * | 2017-12-08 | 2022-08-26 | 주식회사 보령 | Pi3 키나아제 억제제 및 bcl-2 억제제를 포함하는 조성물 |
US20190240198A1 (en) * | 2018-02-05 | 2019-08-08 | Dean G. Tang | Formulations and methods for the treatment of cancers |
CN110772521A (zh) * | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
BR112020018978A2 (pt) | 2018-07-31 | 2021-03-02 | Ascentage Pharma (Suzhou) Co., Ltd. | produto de combinação que compreende um inibidor de bcl-2 e um inibidor de mdm2 e uso dos ditos inibidores na prevenção e/ou tratamento de câncer |
EP3672595B1 (en) | 2018-07-31 | 2021-07-21 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
GEP20237460B (en) | 2018-07-31 | 2023-01-25 | Ascentage Pharma Suzhou Co Ltd | Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop |
CN113164487A (zh) | 2018-10-12 | 2021-07-23 | 内布拉斯加大学董事委员会 | 磷酸二酯酶抑制剂 |
WO2020132563A1 (en) * | 2018-12-21 | 2020-06-25 | Mei Pharma, Inc. | Combination therapy |
CN111377929A (zh) * | 2018-12-28 | 2020-07-07 | 南京艾德凯腾生物医药有限责任公司 | 一种可用于治疗白血病阿卡替尼(Acalabrutinib)制备的方法 |
US20220323376A1 (en) * | 2019-05-01 | 2022-10-13 | New York University | Methods and compositions for sensitizing cancer cells to drug-induced apoptosis |
EP3843751B1 (en) * | 2019-07-31 | 2024-03-27 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of a bcl-2/bcl-xl inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
TWI772992B (zh) * | 2019-12-03 | 2022-08-01 | 大陸商蘇州亞盛藥業有限公司 | 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物 |
EP4000624A1 (en) * | 2020-01-08 | 2022-05-25 | Telios Pharma, Inc. | Btk inhibitors for treating splenomegaly |
US20240024314A1 (en) | 2020-01-08 | 2024-01-25 | Telios Pharma, Inc. | Methods of Treating Splenomegaly |
US20230059785A1 (en) * | 2020-02-07 | 2023-02-23 | University Health Network | Methods for enhancing t cells using venetoclax |
WO2022056092A1 (en) * | 2020-09-11 | 2022-03-17 | Cti Biopharma Corp. | Methods of treating viral infection |
WO2022256489A1 (en) * | 2021-06-02 | 2022-12-08 | Beigene, Ltd. | Methods of treating b-cell malignancy using bcl-2 inhibitor |
EP4346834A1 (en) * | 2021-06-04 | 2024-04-10 | Janssen Pharmaceutica NV | Inhibitors of bruton's tyrosine kinase and methods of their use |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID29028A (id) | 1998-09-18 | 2001-07-26 | Basf Ag | Pirolopirimidina sebagai penghambat protein kinase |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
KR20020063854A (ko) | 1999-09-17 | 2002-08-05 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 키나제 억제제 |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
AP2006003620A0 (en) | 2003-10-15 | 2006-06-30 | Osi Pharm Inc | Imidazopyrazine tyroshine kinase inhibitors |
MXPA06011423A (es) | 2004-04-02 | 2007-01-23 | Osi Pharm Inc | Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico. |
RS55551B1 (sr) | 2004-05-13 | 2017-05-31 | Icos Corp | Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta |
US8153630B2 (en) | 2004-11-17 | 2012-04-10 | Miikana Therapeutics, Inc. | Kinase inhibitors |
RS52642B (en) | 2004-11-18 | 2013-06-28 | Synta Pharmaceuticals Corp. | TRIAZOLE COMPOUNDS MODULATING HSP90 ACTIVITY |
DK1846394T3 (da) | 2005-02-04 | 2012-01-16 | Astrazeneca Ab | Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer |
PT1858644E (pt) | 2005-02-18 | 2013-02-22 | Univ Hong Kong Polytechnic | Método para hidrossililação assimétrica de cetonas |
KR101487027B1 (ko) | 2005-09-30 | 2015-01-28 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
JP2009513615A (ja) | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための4−(3−アミノピラゾール)ピリミジン誘導体 |
PT1951730E (pt) | 2005-11-16 | 2010-08-27 | S Bio Pte Ltd | Derivados de pirimidina ligados a heteroalquilo |
ES2436877T3 (es) | 2005-11-17 | 2014-01-07 | OSI Pharmaceuticals, LLC | Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados |
AU2006316322B2 (en) | 2005-11-22 | 2011-08-25 | Merck Canada Inc. | Tricyclic compounds useful as inhibitors of kinases |
PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
ES2612196T3 (es) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus |
EP1968579A1 (en) | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2007106503A2 (en) | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
LT2530083T (lt) | 2006-09-22 | 2016-09-26 | Pharmacyclics Llc | Brutono tirozinkinazės inhibitoriai |
CN101861313B (zh) | 2007-03-12 | 2014-06-04 | Ym生物科学澳大利亚私人有限公司 | 苯基氨基嘧啶化合物及其用途 |
NZ579834A (en) | 2007-03-23 | 2012-03-30 | Amgen Inc | Heterocyclic compounds as selective inhibitors of PI3K activity |
US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
EP2561875A3 (en) | 2007-03-28 | 2013-06-12 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
EP2166849A4 (en) | 2007-06-11 | 2010-09-15 | Miikana Therapeutics Inc | SUBSTITUTED PYRAZOL COMPOUNDS |
EP2173752B2 (en) | 2007-06-13 | 2022-07-13 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
WO2009076170A2 (en) | 2007-12-13 | 2009-06-18 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
KR20120108042A (ko) | 2008-03-11 | 2012-10-04 | 인사이트 코포레이션 | Jak 억제제로서의 아제티딘 및 시클로부탄 유도체 |
KR101892989B1 (ko) | 2008-06-27 | 2018-08-30 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
US9095592B2 (en) | 2008-11-07 | 2015-08-04 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
AU2009319894A1 (en) | 2008-11-26 | 2010-06-03 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
PA8851101A1 (es) | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
RU2538965C2 (ru) | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
JP5263304B2 (ja) | 2009-02-06 | 2013-08-14 | 日本新薬株式会社 | アミノピラジン誘導体及び医薬 |
DK2401267T3 (en) | 2009-02-27 | 2014-03-10 | Ambit Biosciences Corp | JAK-kinase modulating quinazoline derivatives AND THEIR APPLICATION IN PROCESSES |
EP2424368B1 (en) | 2009-04-29 | 2014-12-31 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
TWI484962B (zh) | 2009-05-22 | 2015-05-21 | Incyte Corp | 作為jak抑制劑之3-〔4-(7h-吡咯并〔2,3-d〕嘧啶-4-基)-1h-吡唑-1-基〕辛烷或庚腈 |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
SG10201704742YA (en) | 2009-05-26 | 2017-07-28 | Abbvie Ireland Unlimited Co | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
WO2011025685A1 (en) | 2009-08-24 | 2011-03-03 | Merck Sharp & Dohme Corp. | Jak inhibition blocks rna interference associated toxicities |
ES2505270T3 (es) | 2009-09-03 | 2014-10-09 | Bristol-Myers Squibb Company | Inhibidores de JAK2 y su uso para el tratamiento de enfermedades mieloproliferativas y cáncer |
EP2486041B1 (en) | 2009-10-09 | 2013-08-14 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
WO2011095556A1 (en) | 2010-02-08 | 2011-08-11 | N.V. Organon | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds |
UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
SG185617A1 (en) | 2010-05-31 | 2012-12-28 | Ono Pharmaceutical Co | Purinone derivative |
CN103153311A (zh) | 2010-06-03 | 2013-06-12 | 药品循环公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
US20120053189A1 (en) | 2010-06-28 | 2012-03-01 | Pharmacyclics, Inc. | Btk inhibitors for the treatment of immune mediated conditions |
CA2807051A1 (en) | 2010-08-10 | 2012-02-16 | Celgene Avilomics Research, Inc. | Besylate salt of a btk inhibitor |
JPWO2012020786A1 (ja) | 2010-08-11 | 2013-10-28 | 日本新薬株式会社 | 医薬組成物 |
JP5668756B2 (ja) | 2010-08-11 | 2015-02-12 | 日本新薬株式会社 | 悪性リンパ腫治療剤 |
ES2581840T3 (es) | 2010-09-01 | 2016-09-07 | Ambit Biosciences Corporation | Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma |
EP2663553B1 (en) | 2010-09-01 | 2015-08-26 | Ambit Biosciences Corporation | Quinoline and isoquinoline derivatives for use as jak modulators |
US20130225614A1 (en) | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 4-azolylaminoquinazoline derivatives and methods of use thereof |
CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
EP2640384A1 (en) | 2010-11-18 | 2013-09-25 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
WO2012068483A1 (en) | 2010-11-18 | 2012-05-24 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment based on hypoxic status |
CN107266435A (zh) | 2010-11-23 | 2017-10-20 | Abbvie 公司 | 细胞凋亡诱导剂的盐和晶形 |
CN103402521B (zh) | 2010-11-23 | 2016-01-20 | 艾伯维巴哈马有限公司 | 使用选择性的bcl-2抑制剂的治疗方法 |
SG190950A1 (en) | 2010-12-03 | 2013-07-31 | Ym Biosciences Australia Pty | Treatment of jak2-mediated conditions |
BR112013017670B1 (pt) | 2011-01-10 | 2022-07-19 | Infinity Pharmaceuticals, Inc | Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas |
WO2012141796A2 (en) | 2011-02-24 | 2012-10-18 | Synta Pharmaceuticals Corp. | Prostate cancer therapy with hsp90 inhibitory compounds |
WO2012116247A1 (en) | 2011-02-25 | 2012-08-30 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
WO2012135937A1 (en) | 2011-04-04 | 2012-10-11 | Pharmascience Inc. | Protein kinase inhibitors |
CA2760174A1 (en) | 2011-12-01 | 2013-06-01 | Pharmascience Inc. | Protein kinase inhibitors and uses thereof |
WO2012155063A1 (en) | 2011-05-11 | 2012-11-15 | Synta Pharmaceuticals Corp. | Treating cancer with an hsp90 inhibitory compound |
DK2710007T3 (da) | 2011-05-17 | 2020-01-27 | Principia Biopharma Inc | Kinasehæmmere |
US20140228418A1 (en) | 2011-05-23 | 2014-08-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
EP2714038A1 (en) | 2011-05-24 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors |
EP2714033A1 (en) | 2011-05-26 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with chk inhibitors |
AU2012275275A1 (en) | 2011-06-28 | 2014-01-23 | Pharmacyclics Llc | Methods and compositions for inhibition of bone resorption |
WO2013006864A2 (en) | 2011-07-07 | 2013-01-10 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
EA201490265A1 (ru) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
KR20140063605A (ko) | 2011-07-19 | 2014-05-27 | 인피니티 파마슈티칼스, 인코포레이티드 | 헤테로사이클릭 화합물 및 그의 용도 |
WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
AU2012285988B2 (en) | 2011-07-19 | 2017-05-25 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides Btk-inhibitors |
LT2734522T (lt) | 2011-07-19 | 2019-02-11 | Merck Sharp & Dohme B.V. | 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk-inhibitoriai |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
AU2012299177A1 (en) | 2011-08-19 | 2014-04-10 | Synta Pharmaceuticals Corp. | Combination cancer therapy of HSP90 inhibitor with antimetabolite |
MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
AU2012325804B2 (en) | 2011-10-19 | 2017-09-07 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US8628752B2 (en) | 2011-10-28 | 2014-01-14 | Synta Pharmaceuticals Corp. | Methods of identifying HSP90 inhibitors with less ocular toxicity |
AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
EP2773345A1 (en) | 2011-11-02 | 2014-09-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
KR102021651B1 (ko) | 2011-11-29 | 2019-09-16 | 오노 야꾸힝 고교 가부시키가이샤 | 퓨리논 유도체 염산염 |
US20140212425A1 (en) | 2011-12-05 | 2014-07-31 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
US20150099721A1 (en) | 2012-05-10 | 2015-04-09 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
WO2013170182A1 (en) | 2012-05-11 | 2013-11-14 | Synta Pharmaceuticals Corp. | Treating cancer with an hsp90 inhibitory compound |
EP2849853A1 (en) | 2012-05-16 | 2015-03-25 | Synta Pharmaceuticals Corp. | Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status |
SG10201610416TA (en) | 2012-06-13 | 2017-01-27 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
ES2717279T3 (es) | 2012-08-17 | 2019-06-20 | Concert Pharmaceuticals Inc | Baricitinib deuterada |
CN111481552A (zh) * | 2012-09-07 | 2020-08-04 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
US9481682B2 (en) | 2013-01-23 | 2016-11-01 | Merck Sharp & Dohme Corp. | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors |
WO2014159745A1 (en) | 2013-03-14 | 2014-10-02 | Pharmacyclics, Inc. | Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors |
WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
EP2983670A4 (en) * | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
CA2914284A1 (en) * | 2013-05-30 | 2014-12-04 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
US20150005277A1 (en) | 2013-06-28 | 2015-01-01 | Beigene, Ltd. | Protein Kinase Inhibitors and Uses Thereof |
WO2015018522A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
CN105848680A (zh) * | 2013-10-25 | 2016-08-10 | 药品循环有限责任公司 | 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗 |
US10328080B2 (en) * | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
WO2015193740A2 (en) * | 2014-06-17 | 2015-12-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor |
WO2016022853A1 (en) | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
EP3179991B1 (en) * | 2014-08-11 | 2021-10-06 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
WO2016024227A1 (en) * | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
HUE059131T2 (hu) * | 2014-08-11 | 2022-10-28 | Acerta Pharma Bv | BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja |
WO2016024232A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
US9717745B2 (en) * | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
FI3954690T3 (fi) * | 2015-07-02 | 2023-05-31 | Acerta Pharma Bv | (s)-4-(8-amino-3-(1-(but-2-ynoyyli)pyrrolidin-2-yyli)imidazo[1,5-a]pyratsin-1-yyli)-n-(pyridin-2-yyli)bentsamidin kiinteitä muotoja ja formulaatioita |
US20170071962A1 (en) * | 2015-09-11 | 2017-03-16 | Acerta Pharma B.V. | Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor |
KR20190058550A (ko) * | 2016-09-19 | 2019-05-29 | 메이 파마, 아이엔씨. | 병용 요법 |
US20190376971A1 (en) * | 2017-01-19 | 2019-12-12 | Acerta Pharma B.V. | Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase |
-
2015
- 2015-08-11 EP EP15757002.9A patent/EP3179991B1/en active Active
- 2015-08-11 LT LTEPPCT/IB2015/056126T patent/LT3179991T/lt unknown
- 2015-08-11 US US15/503,217 patent/US20170231986A1/en not_active Abandoned
- 2015-08-11 WO PCT/IB2015/056126 patent/WO2016024230A1/en active Application Filing
- 2015-08-11 ES ES15757002T patent/ES2900184T3/es active Active
- 2015-08-11 PL PL15757002T patent/PL3179991T3/pl unknown
- 2015-08-11 HU HUE15757002A patent/HUE056329T2/hu unknown
- 2015-08-11 SI SI201531754T patent/SI3179991T1/sl unknown
- 2015-08-11 DK DK15757002.9T patent/DK3179991T3/da active
- 2015-08-11 PT PT157570029T patent/PT3179991T/pt unknown
- 2015-08-11 TW TW104126105A patent/TW201618772A/zh unknown
- 2015-08-11 HR HRP20211813TT patent/HRP20211813T1/hr unknown
- 2015-08-11 RS RS20211442A patent/RS62713B1/sr unknown
-
2018
- 2018-05-17 US US15/982,525 patent/US11166951B2/en active Active
-
2021
- 2021-07-08 US US17/370,827 patent/US11654143B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RS62713B1 (sr) | 2022-01-31 |
TW201618772A (zh) | 2016-06-01 |
ES2900184T3 (es) | 2022-03-16 |
PL3179991T3 (pl) | 2022-02-14 |
US20170231986A1 (en) | 2017-08-17 |
SI3179991T1 (sl) | 2022-04-29 |
US20180250298A1 (en) | 2018-09-06 |
DK3179991T3 (da) | 2021-12-06 |
PT3179991T (pt) | 2021-11-26 |
LT3179991T (lt) | 2021-11-10 |
EP3179991B1 (en) | 2021-10-06 |
WO2016024230A1 (en) | 2016-02-18 |
US20220088013A1 (en) | 2022-03-24 |
US11654143B2 (en) | 2023-05-23 |
EP3179991A1 (en) | 2017-06-21 |
US11166951B2 (en) | 2021-11-09 |
HUE056329T2 (hu) | 2022-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211813T1 (hr) | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 | |
HRP20220738T1 (hr) | Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1 | |
RU2016122232A (ru) | Комбинированная терапия на основе антитела к cd20 и ингибитора втк | |
HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
BR112015008365A2 (pt) | composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente | |
MX2016005666A (es) | Anticuerpos anti-cd38 especificos para tratar canceres humanos. | |
JP2017530950A5 (hr) | ||
JP2019517485A5 (hr) | ||
CU20150020A7 (es) | Composición farmacéutica recubierta que contiene regorafenib | |
JP2016521266A5 (hr) | ||
IL232267A (en) | Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective | |
HRP20192100T1 (hr) | Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe | |
IL240731B (en) | An antibody that binds the p19 subunit of il-23, its production process, a pharmaceutical preparation containing it and its use in cancer treatment | |
BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
CY1119391T1 (el) | Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης | |
ECSP18038867A (es) | Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico h4 (h4) | |
WO2015130554A3 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith | |
TW201613577A (en) | Pharmaceutical combinations | |
MX369518B (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
HRP20210838T1 (hr) | Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe | |
DOP2016000003A (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán | |
MX358501B (es) | Combinación farmacéutica de sinergia para el tratamiento del carcinoma de célula escamosa de cabeza y cuello. |